PALB2 and pachyonychia congenita: Currently, no predictive factors exist to guide treatment selection in advanced PC, with the exception of DNA damage repair alterations such as mutations of BRCA1, BRCA2, and PALB2. Indeed, BRCA1/2 and PALB2 mutations confer sensitivity to platinum-containing chemotherapy,8,9 and germline BRCA1/2 mutations open the possibility to maintenance treatment with olaparib.10